13 March 2026 Punjab Khabarnama Bureau : Indian biotechnology company Bharat Biotech has celebrated three decades of scientific excellence, marking 30 years of contributions to vaccine research, development, and global public health.
Founded in 1996, the Hyderabad-based company has grown into one of India’s leading biotechnology firms, known for developing innovative vaccines that have been distributed in numerous countries. Over the years, the company has focused on addressing infectious diseases through research-driven biotechnology solutions.
Bharat Biotech gained global recognition for developing Covaxin, one of the vaccines used in India’s fight against the COVID-19 pandemic. The vaccine was developed in collaboration with the Indian Council of Medical Research, highlighting the importance of public-private partnerships in healthcare innovation.
The company’s vaccine portfolio includes immunizations targeting diseases such as rotavirus, typhoid, hepatitis, and Japanese encephalitis. These vaccines have played a crucial role in protecting millions of people, particularly in developing countries.
As part of its 30-year celebration, Bharat Biotech highlighted its commitment to research, manufacturing excellence, and global health initiatives. The company has invested heavily in advanced biotechnology infrastructure and large-scale vaccine production facilities.
Executives at the company said the milestone reflects decades of dedication from scientists, researchers, and healthcare professionals who have worked to create safe and effective vaccines. They also emphasized the importance of innovation in addressing emerging health challenges.
Bharat Biotech’s vaccines are now supplied to many countries across Asia, Africa, and Latin America, helping strengthen immunization programs and improve access to essential vaccines worldwide.
Industry experts say the company’s growth demonstrates India’s increasing role in global biotechnology and pharmaceutical innovation. India has become a major hub for vaccine production, supplying a significant portion of the world’s vaccine demand.
Looking ahead, Bharat Biotech plans to continue expanding its research efforts in areas such as next-generation vaccines, biotechnology platforms, and emerging infectious diseases.
The company also aims to strengthen global collaborations with research institutions, health organizations, and governments to improve vaccine access and public health outcomes.
As Bharat Biotech celebrates this milestone, it highlights the importance of sustained scientific research and innovation in building a healthier future for people around the world.
Summary:
Bharat Biotech marked 30 years of innovation in vaccine development, highlighting achievements such as Covaxin and its role in global immunization efforts while reaffirming its commitment to future healthcare research.